Steffensrud S, Erichsen H, Røysland P, Halvorsen T B, Klepp R, Klepp O, Wünsch E, Petersen H
Scand J Gastroenterol. 1984 Oct;19(7):909-15.
Secretin and cholecystokinin (CCK) have trophic effects on the pancreas and may therefore have a place in the treatment of pancreatic cancer. The present study was performed to examine whether these hormones may cause harm in patients with pancreatic cancer receiving cytostatics. The cytostatics were 5-fluorouracil, adriamycin, and mitomycin C(FAM). Secretin plus Thr28Nle31CCK25-33, in doses stimulating pancreatic secretion to about 60% of maximal, were given as a continuous 6-day intravenous infusion just before (four patients) or immediately after (five patients) starting treatment with FAM. Five patients received FAM only. When considering symptoms, laboratory findings, abdominal CT scans, and survival, no evidence was found that secretin and CCK may cause serious or unpleasant side effects in patients with pancreatic cancer receiving cytostatics.
促胰液素和胆囊收缩素（CCK）对胰腺具有营养作用，因此可能在胰腺癌治疗中占有一席之地。本研究旨在检验这些激素是否会对接受细胞抑制剂治疗的胰腺癌患者造成损害。细胞抑制剂为5-氟尿嘧啶、阿霉素和丝裂霉素C（FAM）。在开始使用FAM治疗前（4例患者）或治疗后立即（5例患者），以刺激胰腺分泌至最大分泌量约60%的剂量，持续6天静脉输注促胰液素加Thr28Nle31CCK25 - 33。5例患者仅接受FAM治疗。在考虑症状、实验室检查结果、腹部CT扫描和生存率时，未发现证据表明促胰液素和CCK会对接受细胞抑制剂治疗的胰腺癌患者造成严重或不良副作用。
